Market Assessment
In Q2/2019, Hepion Pharmaceuticals (HEPA) started a “new clinical life” with a name change from ContraVir Pharmaceuticals (CTRV). It also streamlined its clinical program with a focus on CRV431 in NASH and Hepatitis B infection. The timeline revealed by the company showed that the Phase 2 safety and efficacy study of CRV431 in NASH will be initiated at the earliest Q4/2020 (Fig. 1).
Fig. 1: Proposed timeline of events for the clinical development of CRV431 for NASH
Between now and then, HEPA will undertake preclinical and toxicology/carcinogenicity studies as is required